Skip to main content
. 2022 May 13;14(2):435–464. doi: 10.1016/j.jcmgh.2022.05.003

Figure 7.

Figure 7

Fzd5,8-specific SZN-1326-p repaired DSS damaged colon and improved DAI and inflammation. (A) Diagram illustrating the acute DSS study design. (B–G) H&E stain of transverse colon sections of animals treated (B) with no DSS or (C) with DSS with PBS, (D) with anti-GFP, (E) with 2 doses of 10 mg/kg R2M3-26, (F) with 2 doses of 10 mg/kg SZN-1326-p, and (G) with 2 doses of 3 mg/kg 1RC07-26. Scale bar = 200 μm. (H) Daily animal fecal score of each treatment group. (I) Disease activity (DAI) progression for each treatment group. (J) Composite histology score reading by an independent pathologist, on colon samples harvested at termination. (K–M) Effect of Wnt mimetics on serum level of proinflammatory cytokines, (K) TNF-α, (L) IL-6, (M) IL-8. (N-P) Effect of a wide dose range of SZN-1326-p, both as a single dose (N) or as twice weekly doses (O), on DAI and colon histology score (P). Statistical analysis was performed as described in the Materials and Methods with all comparisons made with the anti-GFP group.